13558 (consultation sur place) - Monographie
Anticoagulation therapy supplement
Bloomington, MN : Institute for clinical systems improvement, 2001, 54 p. (03-06-2005)
Collection : Health Care Guidelines
Format de fichier : Adobe Acrobat PDF
Droits d'auteur : Cette oeuvre est protégée par un droit d'auteur. Elle ne peut être reproduite qu'à des fins d'études privées ou de recherche et seulement si la source est mentionnée.

Mots-clés principaux

Résumé :

The ICSI Anticoagulation Therapy Supplement has been developed as a ressource for the use of a anticoagulant drugs. This is a supplemental document that brings about consistency in recommendations that are common to the scope of related ICSI cardiovascular guidelines : Atrial Fibrillation, Congestive Heart Failure, Diagnosis and Initial Treatment of Ischemic Stroke, Treatment of Acute Myocardial Infarction, and Venous Thromboembolism.

Anticoagulant drugs are used to decrease the risk of thrombosis by interfering with the homeostatic clotting mechanism. The major side effect of these drugs is bleeding either from supratherapeutic effect or by accentuating the blood loss of patients with an existing source of bleeding.

There are no absolute contraindications to anticoagulation therapy. The decision to treat a patient with anticoagulant drugs takes into account an individual patient's risk for thrombosis if not treated weighed against the risk of bleeding while on anticoagulation therapy. This supplement and related guidelines should help physicians to make that risk-benefit treatment decision. This supplement is also meant to serve as a tool to use for patients treated with anticoagulants.

Langue : Anglais
Type d'ouvrage AQESSS : lignedir
Doc n° : 13558
NumRec : 1355803


  Copier Permanent URL de cette page Ajouter cette page


consultation sur place

Aller vers :   IUGM    Fondation IUGM   Centre de recherche IUGM